⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14305909 | 0.81 | LMNA (0.55) | — | |
| SCHEMBL6303637 | 0.79 | TSHR (0.57) | — | |
| Succinic Acid SCHEMBL3039750 | 0.78 | LMNA (0.64) | — | |
| SCHEMBL9061995 | 0.77 | GRM8 (0.59) | — | |
| SCHEMBL2403116 | 0.73 | GRM8 (0.61) | — | |
| Succinic Acid SCHEMBL3039744 | 0.73 | LMNA (0.56) | — | |
| SCHEMBL23648 | 0.73 | — | — | |
| SCHEMBL14305914 | 0.72 | LMNA (0.50) | — | |
| SCHEMBL11089864 | 0.71 | FOLH1 (0.52) | — | |
| Ammonia Solution, Strong SCHEMBL28215144 | 0.71 | FOLH1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3469084-A1 | HIGH SPECIFICITY GENOME EDITING USING CHEMICALLY MODIFIED GUIDE RNAS | Agilent Technologies, Inc. (US) | 2019-04-17 | — | — | EP | claimed |
| WO-2017214460-A1 | HIGH SPECIFICITY GENOME EDITING USING CHEMICALLY MODIFIED GUIDE RNAS | AGILENT TECHNOLOGIES, INC. (US) | 2017-12-14 | — | — | WO | claimed |
| CN-116676305-A | High specificity genome editing using chemically modified guide RNAs | 安捷伦科技有限公司 | 2023-09-01 | — | — | CN | disclosed |
| EP-3469084-A1 | HIGH SPECIFICITY GENOME EDITING USING CHEMICALLY MODIFIED GUIDE RNAS | Agilent Technologies, Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| US-10010618-B2 | Methods for treating cancer using combination therapies | ENDOCYTE, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-9951324-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2018-04-24 | — | — | US | disclosed |
| WO-2017214460-A1 | HIGH SPECIFICITY GENOME EDITING USING CHEMICALLY MODIFIED GUIDE RNAS | AGILENT TECHNOLOGIES, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20160296630-A1 | METHODS FOR TREATING CANCER USING COMBINATION THERAPIES | ENDOCYTE INC (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160151508-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2016-06-02 | — | — | US | disclosed |
| US-20160151508-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2016-06-02 | — | — | US | disclosed |
| US-20140154702-A1 | Methods For Treating Cancer Using Combination Therapies | ENDOCYTE INC (US) | 2014-06-05 | — | — | US | disclosed |
| WO-2009016520-A2 | THIOPHOSPHI(O)NIC ACID DERIVATIVES AND THEIR USE AS AGONISTS OR ANTAGONISTS FOR METABOTROPIC GLUTAMATE RECEPTORS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2009-02-05 | — | — | WO | disclosed |
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | KIACTA SARL (CH) | 2006-06-01 | — | — | US | disclosed |
| US-6670399-B2 | Contacting a blood vessel wall cell with an A beta 40 inhibitor, such that cerebral amyloid angiopathy is inhibited | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2003-12-30 | — | — | US | disclosed |
| EP-1251837-A2 | COMPOUNDS AND METHODS FOR MODULATING CEREBRAL AMYLOID ANGIOPATHY | Neurochem, Inc. (CA) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001085093-A2 | COMPOUNDS AND METHODS FOR MODULATING CEREBRAL AMYLOID ANGIOPATHY | NEUROCHEM, INC. (US) | 2001-11-15 | — | — | WO | disclosed |
| EP-1100487-A2 | COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTIONS | Neurochem, Inc. (CA) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000006133-A2 | COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTIONS | NEUROCHEM, INC. (CA) | 2000-02-10 | — | — | WO | disclosed |